Table 1 Patient’s characteristics including sample type, BCR-ABL1/ABL1 ratio before/after imatinib therapy for responders (R) and non-responders (NR)
Patient identifier | Age (at time of sampling) | Sample type | Gender | Response | BCR-ABL1/ABL1 ratio (at time of sampling) | BCR-ABL1/ABL1 ratio (after 18 months) |
|---|---|---|---|---|---|---|
01 | 62 | PB | M | R | 0.8 | 8·10−4 |
02 | 42 | PB | M | R | 0.7 | 4·10−4 |
03 | 63 | PB | F | R | 0.8 | 9·10−4 |
04 | 63 | PB | M | R | 0.8 | 7·10−4 |
05 | 45 | PB | F | R | 0.5 | 1·10−4 |
06 | 27 | PB | M | R | 0.8 | 7·10−5 |
07 | 54 | PB | F | R | 0.8 | 7·10−4 |
08 | 50 | PB | M | R | 0.4 | 6·10−4 |
09 | 47 | PB | M | R | 0.4 | 3·10−5 |
10 | 71 | PB | M | R | 0.5 | 2·10−5 |
11 | 57 | PB | M | R | 0.9 | 8·10−4 |
12 | 61 | PB | F | R | 0.7 | 4·10−4 |
Median BCR-ABL1/ABL1 ratio of PB responders | 0.75 | 5·10−4 | ||||
13 | 81 | PB | F | NR | n.d | 1·100 |
14 | 79 | PB | M | NR | 0.8 | 2·10−1 |
15 | 71 | PB | M | NR | n.d | 2·10−1 |
16 | 46 | PB | M | NR | n.d | 1.1·100 |
17 | 50 | PB | M | NR | 0.6 | 5·10−1 |
18 | 82 | PB | F | NR | 0.2 | 2·10−1 |
19 | 78 | PB | F | NR | 0.3 | 3·10−1 |
20 | 54 | PB | F | NR | 0.5 | 4·10−1 |
21 | 54 | PB | M | NR | 0.9 | 2·10−2 |
22 | 86 | PB | F | NR | 0.1 | 1·10−1 |
23 | 77 | PB | F | NR | 0.5 | 2·10−1 |
24 | 20 | PB | M | NR | 0.7 | 7·10−1 |
25 | 42 | PB | M | NR | 1.5 | 9·10−1 |
26 | 62 | PB | F | NR | 0.4 | 2·10−1 |
27 | 54 | PB | M | NR | 0.4 | 3·10−2 |
28 | 46 | PB | M | NR | 1.0 | 3·10−1 |
Median BCR-ABL1/ABL1 ratio of PB non-responders | 0.5 | 2.5·10−1 | ||||
29 | 30 | BM | M | R | 0.3 | 7·10−4 |
30 | 52 | BM | M | R | 1.1 | 1·10−3 |
31 | 71 | BM | F | R | 0.8 | 2·10−4 |
32 | 70 | BM | F | R | 0.7 | 7·10−5 |
33 | 41 | BM | F | R | 1.3 | 2·10−3 |
34 | 72 | BM | M | R | 1.0 | 3·10−4 |
35 | 56 | BM | M | R | 0.4 | 6·10−4 |
36 | 81 | BM | M | R | 1.0 | 1·10−4 |
37 | 38 | BM | M | R | 0.6 | 1·10−4 |
38 | 69 | BM | M | R | 1.1 | 3·10−4 |
39 | 49 | BM | M | R | 1.3 | 4·10−4 |
40 | 71 | BM | M | R | 2.1 | 5·10−4 |
41 | 67 | BM | F | R | 1.0 | 8·10−5 |
42 | 80 | BM | M | R | 0.7 | 2·10−4 |
Median BCR-ABL1/ABL1 ratio of BM responders | 0.7 | 3.5·10−4 | ||||
43 | 72 | BM | F | NR | 0.7 | 5·10−1 |
44 | 43 | BM | F | NR | 0.6 | 2·10−2 |
45 | 19 | BM | M | NR | 0.7 | 5·10−2 |
Median BCR-ABL1/ABL1 ratio of BM non-responders | 0.7 | 5·10−2 | ||||